(SGMO) Sangamo Therapeutics - Ratings and Ratios

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is a clinical-stage genomic medicine company dedicated to developing innovative therapies that address severe diseases. The companys pipeline includes several notable product candidates: ST-920, a gene therapy for Fabry disease in Phase 1/2; TX200, a CAR-Treg therapy for kidney transplant rejection in Phase 1/2; SB-525, a gene therapy for hemophilia A in Phase 3; and BIVV003, a gene-edited cell therapy for sickle cell disease in Phase 1/2. Their preclinical work focuses on CAR-Treg therapies for autoimmune diseases and genome editing for neurological disorders.

Sangamo has established strategic partnerships with major pharmaceutical companies, including Biogen, Pfizer, and Sanofi, enhancing its research and development capabilities. The company, renamed from Sangamo BioSciences in 2017, is headquartered in Richmond, California, and has been a pioneer in genomic medicine since its incorporation in 1995.

3-Month Forecast: Based on the provided data, SGMOs stock is expected to experience volatility. The stock is trading below its 20, 50, and 200-day SMAs, indicating bearish momentum. Key resistance levels at $2.3 and $1.9, and a support level at $0.5, suggest potential price movements. The Average True Range of $0.15 indicates moderate price fluctuations.

Fundamentally, SGMOs high P/B ratio of 5.76 and P/S ratio of 3.99 may signal overvaluation. The companys progress in clinical trials, particularly for SB-525 and BIVV003, will be critical for stock performance. Positive trial results could counterbalance negative technical indicators and high valuations, potentially improving investor sentiment and stock price.